

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 7,652,054)
)
Inventors: Mathias Alterman et al.)
)
Issued: January 26, 2010)
)
For: Tricyclic Compounds Useful as)
 Angiotensin II Agonists)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. § 255, and 37 C.F.R. § 1.323, this is a request for a Certificate of Correction in the above-identified patent. The mistake identified in the appended Form is of a clerical or typographical nature, or of minor character, and resulted from an error made in good faith by Patentee. Pursuant to 37 C.F.R. § 1.20(a), Patentee includes payment in the amount of \$100.

The mistake identified in the appended Form is that in Claim 1, col. 35, lines 59-65,

“R⁵ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl or di-C₁₋₃-alkylamino-C₁₋₄-alkyl;

R⁶ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl, and

C₁₋₃ alkoxy-C₁₋₆-alkoxy, C₁₋₆ alkylamino or di-C₁₋₆ alkylamino

or a pharmaceutically-acceptable salt thereof.”

should read

-- R⁵ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl or
di-C₁₋₃-alkylamino-C₁₋₄-alkyl; and

R⁶ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl,
C₁₋₃ alkoxy-C₁₋₆-alkoxy, C₁₋₆ alkylamino or di-C₁₋₆ alkylamino,
or a pharmaceutically-acceptable salt thereof.--.

The complete Certificate of Correction involves one (1) page. Issuance of the
Certificate of Correction containing the correction is earnestly requested.

Please charge any required fees not included herewith to Deposit Account No.
06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 3, 2010

By: Maryann T. Puglielli

Maryann T. Puglielli
Reg. No. 52,138
(202) 408-6054

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 7,652,054

Page 1 of 1

APPLICATION NO.: 10/721,892

ISSUE DATE: January 26, 2010

INVENTORS: Mathias Alterman et al.

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claim 1, col. 35, lines 59-65,

“R⁵ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl or
di-C₁₋₃-alkylamino-C₁₋₄-alkyl;

R⁶ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl, and
C₁₋₃ alkoxy-C₁₋₆-alkoxy, C₁₋₆ alkylamino or di-C₁₋₆ alkylamino
or a pharmaceutically-acceptable salt thereof.”

should read

-- R⁵ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl or
di-C₁₋₃-alkylamino-C₁₋₄-alkyl; and

R⁶ represents C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-C₁₋₆-alkyl,
C₁₋₃ alkoxy-C₁₋₆-alkoxy, C₁₋₆ alkylamino or di-C₁₋₆ alkylamino,
or a pharmaceutically-acceptable salt thereof.--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413